NCT06235476

Protein Intake and Exercise-induced Muscle Damage

Comparing the Effects of Three PROtein-enhancement Strategies on Exercise-induced Muscle Damage in Older Adults
Radboud University Medical Center·ClinicalTrials.gov·dietary supplementNot yet recruiting
View on ClinicalTrials.gov
Study focus
Disease/Condition
Sarcopenia
Drug/Device/Intervention
whey protein supplement
Study type
Interventional
Intervention type
dietary supplement
Sponsor & location
Primary sponsor
Radboud University Medical Center
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
Aug 31, 2024
Enrollment
200 participants
Primary outcome

serum creatine kinase (CK) levels

Summary

The goal of this clinical trial is to test the effect of different protein-enhancement
 strategies versus carbohydrate control on exercise-induced muscle damage in physically active
 older adults. The main question it aims to answer is:
 
 What is the effect of three different protein-enhancement strategies (whey protein (WP),
 mixed plant-based protein (MPP), and use of protein-rich food products (PFP) on
 exercise-induced muscle damage in older adults compared to isocaloric carbohydrate control?
 
 Participants will:
 
 - Use a protein-enhancement strategy (WP, MPP or PFP) or carbohydrate control for a total
 of 5 weeks;
 
 - Participate in a single walking bound (30/40/50 km) two weeks after the start of the
 study;
 
 - Participate in a consecutive walking bound (4 days of 30/40/50 km) in the last week of
 the study period;
 
 - Complete different questionnaires and give blood samples to test for muscle damage.

ICD-10 classifications
Kaposi sarcomaHerniaTaeniasisTaenia saginata taeniasisDiaphragmatic hernia
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06235476
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06235476 through Pure Global AI's free database. This phase not specified trial is sponsored by Radboud University Medical Center and is currently Not yet recruiting. The study focuses on Sarcopenia. Target enrollment is 200 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.